Isozid

Isoniazid, the active ingredient in Isozid, is an antitubercular agent presented as an injectable solution for intravenous use. It is employed in the treatment of active tuberculosis and in the prophylaxis of latent tuberculosis infection across adult and pediatric populations.

GNH USA supplies Isozid as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation to support import and clinical use. Isozid is manufactured under strict GMP conditions and packaged to maintain sterility throughout distribution.

Isoniazid is used in the antitubercular drug class to manage Mycobacterium tuberculosis infections.

Active tuberculosis: contributes to bacterial eradication and clinical cure when combined with standard multidrug regimens. Latent tuberculosis infection: reduces the risk of progression to active disease when given as prophylaxis.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Peripheral neuropathy (tingling or numbness) - Skin rash or mild fever - Elevated liver enzymes (transaminases)

Serious or Rare Side Effects: - Hepatotoxicity, including severe hepatitis - Severe hypersensitivity reactions such as Stevens‑Johnson syndrome - Drug‑induced lupus erythematosus - Anaphylactic shock or severe allergic reaction

When prescribing Isozid, clinicians should observe several safety measures to minimize risk. - Pregnancy: Category C – use only if potential benefit justifies the risk to the fetus. - Liver function: obtain baseline hepatic enzymes and monitor periodically during therapy. - Neuropathy: consider pyridoxine (vitamin B6) supplementation to prevent peripheral nerve damage. - Concomitant hepatotoxic drugs: avoid or monitor closely when combined with other agents that affect liver. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Isoniazid interacts with several medicines; the nature of the interaction determines the required clinical action.

Major Interactions (Avoid): - Rifampicin: combined use increases hepatotoxic risk and may reduce isoniazid efficacy. - Certain antiretrovirals (e.g., efavirenz): may lead to increased neurotoxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may enhance hepatic enzyme induction, affecting isoniazid metabolism. - Alcohol: concurrent use raises risk of liver injury. - Pyrazinamide: co‑administration can amplify hepatotoxic potential.